CBD for IBS and irritable bowel: what studies say about cannabidiol and the microbiome

Irritable bowel syndrome (IBS) affects 10 to 15% of the population in Western countries and is one of the most common reasons for visits to a gastroenterologist. Abdominal pain, bloating, irregular bowel movements, alternating diarrhea and constipation — these symptoms can drastically reduce quality of life. Conventional treatment for IBS is often unsatisfactory, leading patients to seek alternatives — increasingly, this includes CBD. What does science say about cannabidiol and irritable bowels?

KEY INFORMATION
• Storr et al. (Alimentary Pharmacology and Therapeutics, 2009) described the role of the endocannabinoid system (ECS) in regulating bowel function — ECS is a key regulator of motility, secretion, and visceral sensitivity.
• CBD may reduce visceral hypersensitivity through TRPV1 receptors — a key mechanism in IBS, where the pain threshold for bowel stretching is lowered.
• The gut-brain axis connects the gut to the brain — stress exacerbates IBS, and CBD, by reducing anxiety, may indirectly improve bowel function.
• There is a lack of large randomized clinical trials on CBD + IBS in humans — evidence is promising but preliminary.
• CBD may cause diarrhea as a side effect — an important note for IBS with diarrhea predominance (IBS-D).

How does the endocannabinoid system regulate bowel function?

The endocannabinoid system (ECS) is actively present throughout the gastrointestinal tract — CB1 and CB2 receptors are distributed in enteric cells, the enteric nervous system (ENS), and immune cells in the lamina propria. ECS plays a crucial role in regulating gut motility, secretion of digestive juices, and the perception of visceral pain.

Storr et al. (Alimentary Pharmacology and Therapeutics, 2009) conducted a comprehensive analysis of the role of ECS in the pathophysiology of IBS. CB1 receptors in ENS neurons regulate intestinal contractions — their activation slows motility (THC causes intestinal stasis precisely through CB1). CB2 in intestinal immune cells modulates inflammation and intestinal barrier permeability. TRPV1 receptors (a temperature and capsaicin-activated cation channel) in afferent sensory neurons regulate the threshold for visceral pain — in IBS, TRPV1 receptors are overexpressed, lowering the pain threshold.

CBD acts on all these targets — not only through CB1 and CB2 but primarily through TRPV1 (as an antagonist at higher doses, which reduces hypersensitivity) and through 5-HT4 receptors (serotonin receptors responsible for peristaltic reflex). 95% of serotonin in the body is produced in the gut — CBD, as a modulator of 5-HT4, has the potential to influence motility and pain perception in the gut through a mechanism that does not require activation of CB1 receptors.

The gut-brain axis and IBS: how can CBD help indirectly?

IBS is often described as the “gut-brain axis disease” — a bidirectional network of signals between the brain and the gut, involving the vagus nerve, hormonal system (HPA axis), microbiome, and ENS. Stress and anxiety directly exacerbate IBS symptoms through this axis, which is well documented clinically.

CBD, as a substance with documented anxiolytic properties, may indirectly improve gut function by reducing stress and anxiety that drive IBS symptoms. Mechanism: CBD reduces HPA axis activation (hypothalamus-pituitary-adrenal) through 5-HT1A receptors, which decreases cortisol secretion. High cortisol increases intestinal barrier permeability (“leaky gut”), disrupts microbiome composition, and intensifies visceral hypersensitivity. This is an indirect but biologically plausible mechanism through which CBD may reduce the severity of IBS in patients where stress is a major trigger.

Study Shannon et al. (Permanente Journal, 2019) found that 79.2% of participants with anxiety experienced improvement with CBD — and the improvement in anxiety in IBS patients correlates with improvement in bowel symptoms in many clinical studies. Although the Shannon study did not focus on IBS, the mechanistic connection is clear. IBS patients for whom anxiety is a strong component may benefit from CBD not only through direct effects on the gut but also through anxiety reduction as an exacerbating factor.

Visceral hypersensitivity and TRPV1: the key to pain in IBS

One of the fundamental features of IBS is a lowered pain threshold to stimuli from the gut — a phenomenon called visceral hypersensitivity. The normal degree of stretching of the gut by gas and food content, which is painless in a healthy person, causes pain or discomfort in a patient with IBS. This hypersensitivity is partly due to the overexpression of TRPV1 receptors in afferent sensory neurons of the gut.

Storr et al. (2009) described evidence for the role of TRPV1 in visceral hypersensitivity in IBS — TRPV1 antagonists reduced visceral pain in animal models. CBD, acting as a TRPV1 antagonist (or modulating its activity depending on the dose), may theoretically reduce this component of pain in IBS. This is a biologically plausible and interesting mechanism, although there are very few direct clinical studies on CBD + visceral hypersensitivity in humans.

The study by Roelofs et al. (Journal of Pharmacology and Experimental Therapeutics, 2008) in a mouse model showed that CBD significantly reduced colitis-induced visceral sensitivity through TRPV1 antagonism. Translating these results to IBS in humans requires caution — but the mechanism is relevant. In IBS with a predominant pain component, CBD may be particularly worth exploring precisely because of this mechanism.

Gut microbiome and CBD: what is known?

The gut microbiome — a complex community of billions of bacteria, fungi, and other microorganisms residing in the gut — is increasingly understood as a key factor in IBS. Patients with IBS exhibit gut dysbiosis (disrupted microbiome composition), reduced bacterial diversity, and altered ratios of Firmicutes to Bacteroidetes species.

Preclinical studies on mice suggest that CBD may modulate the composition of the gut microbiome — reducing the proportion of pro-inflammatory species (e.g., Clostridioides) and potentially increasing the proportion of beneficial species (Lactobacillus, Bifidobacterium). The mechanism is partially linked to the action of CBD on CB2 in the intestines (modulating the immune response) and the anti-inflammatory properties of CBD that reduce inflammation of the intestinal wall.

An important caveat: microbiome and CBD studies in humans with IBS are at a very early stage. Clinical data from randomized studies are virtually absent. Results from mouse models cannot be directly transferred to humans — the mouse microbiome differs significantly from the human microbiome in terms of composition. The microbiome is a promising but still speculative mechanism of action for CBD in IBS.

Our observations: Patients with IBS asking about CBD have usually tried many conventional therapies with limited success. The most commonly described effect of CBD in IBS is not "cure," but rather a reduction in the severity of abdominal pain and an improvement in overall comfort during stress — which is consistent with the mechanisms of 5-HT1A and TRPV1. The effects on diarrhea and constipation are more variable and individual. Keeping a symptom diary for 6 weeks is crucial — IBS is a condition with significant natural variability, and without systematic documentation, it is difficult to assess whether CBD is truly helpful.

How to use CBD for IBS? Practical tips

There are no clinically established dosing protocols for CBD in IBS. Based on the mechanisms of action and general principles of CBD use, reasonable practical guidelines can be formulated.

Form of CBD: Sublingual oil is preferred for IBS — high bioavailability (13–19% vs 4–8% when swallowed), faster onset of action (15–45 minutes). Taking it with a meal (especially a fatty one) increases absorption by up to 9.7× according to a study Saals et al. (Scientific Reports, 2025).

Dosing: Start with 10–15 mg of CBD twice daily (in the morning with breakfast and in the evening with dinner). A lower starting point than for other applications is indicated, as the intestines may react to MCT oil (the carrier of CBD) — a higher dose of MCT may itself cause loose stools. Observe for 2 weeks, then increase to 20–25 mg twice daily if the effect is insufficient. Most described effects in chronic GI disorders appear after 4–6 weeks of regular use, not after a few days.

Caution with IBS-D (with diarrhea dominance): CBD may paradoxically exacerbate diarrhea, especially at higher doses or with MCT as a carrier. If you have IBS-D, start with a particularly low dose (5–10 mg) and observe for 2 weeks before increasing. If diarrhea worsens — reduce the dose or consider taking a break.

Caution with IBS-C (with constipation dominance): CBD may potentially improve bowel regularity in IBS-C through stimulation of peristalsis (5-HT4) — this is a biologically justified mechanism, although not clinically confirmed. If you notice an improvement in regularity with CBD, that is a positive sign.

CBD vs other supplements for IBS: where does cannabidiol fit in?

IBS is a condition for which there are several interventions with proven or likely beneficial effects. It is worth understanding where CBD fits into this landscape and what its place is in the hierarchy of available therapeutic options.

Probiotics: They have documented efficacy in IBS in many RCTs — strains of Lactobacillus rhamnosus GG, Bifidobacterium infantis, and VSL#3 have shown improvement in symptoms in clinical studies. Probiotics are the first line of supplementation for IBS — before CBD. CBD may potentially act synergistically with probiotics (CBD normalizes the microbiome + probiotics provide beneficial bacteria), but this synergy has not been clinically studied.

Low-FODMAP diet: The dietary intervention with the strongest level of evidence for IBS — 70–75% of patients experience significant improvement. It is not a supplement, but a starting point for any rational management of IBS. CBD does not replace the low-FODMAP diet and should not be used instead of it. The low-FODMAP diet excludes fermentable oligosaccharides, disaccharides, monosaccharides, and polyols — components that cause bloating and motility changes in patients with IBS. CBD and the low-FODMAP diet can be used concurrently without interaction.

Mebeverine and other antispasmodic medications: First line pharmacotherapy for IBS in Polish guidelines. CBD is a supplement, not an alternative to conventional treatment. Always consult the use of CBD for IBS with a gastroenterologist — especially if you are taking other medications, as CBD may affect their metabolism via cytochrome P450. More about CBD dosing and drug interactions can be found in the article CBD dosing – how many drops to take.

IBS and other inflammatory bowel diseases: when might CBD have stronger foundations?

Although this article focuses on IBS, it is worth mentioning that CBD potentially has stronger scientific foundations in non-specific inflammatory bowel diseases (IBD) — Crohn's disease and ulcerative colitis. In IBD, unlike IBS, we are dealing with documented inflammation of the intestinal lining, where CB2 and the anti-inflammatory mechanisms of CBD are directly relevant.

IBS is a functional disorder (without organic inflammation) — which makes the mechanisms of CBD relevant for IBD potentially less central. However, visceral hypersensitivity (TRPV1), motility (5-HT4), and the gut-brain axis (5-HT1A) are specific to IBS and provide CBD with a distinct mechanistic justification.

In cases of treatment-resistant IBS-C or prolonged abdominal pain, a gastroenterologist may recommend a colonoscopy, fecal calprotectin test, or tests for celiac disease — before you jointly decide to supplement treatment with CBD. It is also important to know that CBD may potentially interact with medications used for IBD (mesalazine, steroids, azathioprine) by inhibiting cytochrome P450 — always inform your gastroenterologist about CBD supplementation.

Important: before using CBD for gastrointestinal symptoms, ensure you have a correct diagnosis of IBS (and not IBD, celiac disease, colon cancer, or another organic disease). IBS is a diagnosis of "exclusion" — gastrointestinal symptoms require gastroenterological diagnostics. CBD does not replace this diagnostics. An article on the impact of CBD on pain is available here: CBD for Pain.

Frequently Asked Questions

Does CBD help with IBS?

Preliminary data suggest that CBD may alleviate IBS symptoms by reducing visceral hypersensitivity (TRPV1), modulating motility (5-HT4), and indirectly reducing anxiety as an exacerbating factor (5-HT1A). Storr et al. (2009) They described the role of the ECS in gut function. However, there are very few solid RCTs for CBD + IBS in humans — preliminary evidence, not conclusive.

How does CBD affect the gut-brain axis?

CBD reduces stress and anxiety through 5-HT1A, which indirectly improves gut function (stress is a key exacerbating factor for IBS). Directly in the gut, CBD acts through TRPV1 (visceral pain), 5-HT4 (peristalsis), and CB2 (inflammation). The multi-level action on the gut-brain axis is biologically justified.

How much CBD should I take for IBS?

Starting point: 10–15 mg CBD twice a day with meals. If insufficient effect after 2 weeks, increase to 20–25 mg twice a day. For IBS-D (diarrhea): start with 5–10 mg and monitor gut tolerance. Assess effectiveness over 4–6 weeks, keeping a symptom diary.

Does CBD affect the gut microbiome?

Preclinical studies in mice suggest a modulatory effect of CBD on the microbiome — reducing pro-inflammatory species, potentially increasing Lactobacillus. However, there is very little solid clinical data in humans with IBS. The microbiome is a promising but preliminary mechanism in the context of CBD and IBS.

Does CBD have side effects with IBS?

CBD may cause diarrhea as a side effect — paradoxically problematic for IBS-D. This effect is partly due to the MCT oil carrier. Start with low doses (5–10 mg) and monitor gut tolerance. For IBS-C (constipation), the effect on motility may be beneficial. Other possible effects: dry mouth, drowsiness at higher doses.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a physician, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04